Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress

- Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection

- 8 Oral & Poster Presentations

VANCOUVER, British Columbia, May 22, 2019 /PRNewswire/ -- Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris' proprietary anti-interleukin-6 humanized monoclonal antibody, have been accepted for presentation at the 2019 American Transplant Congress (ATC) taking place from June 1-5 in Boston, MA. These studies underscore Vitaeris' commitment to developing clazakizumab to address the unmet medical needs of transplant recipients suffering from chronic active antibody-mediated rejection and patients in need of kidney transplants.

ATC 2019 Presentations on Clazakizumab Listed Chronologically:

                   Presentation 
            
              Date/Time/Location

    ---

        Change in               
            Saturday, June 1, 2019, 5:30 pm - 7:30 pm
         eGFR and                         Transplantation.
         Risk of                          Irish W,
         Allograft                        Nickerson P
         Failure in                       et al.
         Patients
         diagnosed
         with Active
         ABMR
         Following
         Kidney

        (POSTER
         Abstract
         A197)                  
            Poster Session A: Kidney Chronic Antibody
                                Mediated Rejection

                                
            Location: Hall C & D

    ---

        Clazakizumab
         acts on
         Endothelial
         Cells to
         limit
         Antibody
         Mediated
         Damage. Lion
         J, Mooney
         NA, Glotz D.           
            Saturday, June 1, 2019, 5:30 pm - 7:30 pm

        (POSTER
         Abstract
         A81)                   
            Poster Session A: Endothelial Cell Biology

                                
            Location: Hall C & D

    ---

        Clazakizumab            
            Saturday, June 1, 2019, 5:30 pm - 7:30 pm
         Treatment of                     et al.
         Patients
         with CABMR
         Reduces
         Total IgG
         and Anti-
         HLA IgG
         Antibody
         Levels. Shin
         B, Jordan S

        (POSTER
         Abstract
         A193)                  
            Poster Session A: Chronic Antibody
                                Mediated Rejection

                                
            Location: Hall C & D

    ---

        Monitoring
         Inflammatory
         Cytokine
         Levels in
         Patients
         with CABMR
         treated with
         Clazakizumab.
         Ge S, Jordan
         S et al.               
            Saturday, June 1, 2019, 5:30 pm - 7:30 pm

        (POSTER
         Abstract
         A179)                  
            Poster Session A: Biomarkers, Immune
                                Monitoring and Outcomes

                                
            Location: Hall C & D

    ---

        Evaluation of           
            Sunday, June 2, 2019, 2:42 pm - 2:54 pm
         the Safety                       ESRD
         and                              Patients. Vo
         Tolerability                     A, Jordan S
         of                               et al.
         Clazakizumab
         as
         Desensitization
         Agent in
         Highly-HLA
         Sensitized

        (ORAL
         Abstract 27)           
            Session: Kidney Immunosuppression:
                                Desensitization

                                
            Location: Ballroom A

    ---

        Clazakizumab            
            Monday, June 3, 2019, 4:30 pm - 4:42 pm
         as Agent to                      Ammerman N
         Reduce HLA                       et al.
         DSA and
         Improve
         Outcomes in
         Patients
         with CABMR
         Post-kidney
         Transplantation.
         Jordan S,

        (ORAL
         Abstract
         316)                   
            Session: Kidney Chronic Antibody Mediated
                                Rejection

                                
            Location: Ballroom B

    ---

        Clazakizumab            
            Monday, June 3, 2019, 4:42 pm - 4:54 pm
         and                              6R and GP130
         Tocilizumab                      in Kidney
         treatments                       Transplant
         differentially                   Patients
         affect IL-                       treated for
         6/IL-6R                          CABMR. Shin
         signalling                       B, Jordan S
         by                               et al.
         modulating
         Soluble IL-

        (ORAL
         Abstract
         317)                   
            Session: Kidney Chronic Antibody Mediated
                                Rejection

                                
            Location: Ballroom B

    ---

         Neutralization         
            Monday, June 3, 2019, 6:00 pm - 7:00 pm
         of IL-6 by                       Sensitization
         Ald518-p18                       - a Dose
         (murine                          Finding
         Clazakizumab)                    Study. Wu G,
         Attenuates                       Jordan S et
         DSA                              al.
         Responses in
         Mouse Model
         of
         Allogeneic

        (POSTER
         Abstract
         C14)                   
            Poster Session C: Immunosuppression
                                Preclinical Studies

                                
            Location: Hall C & D

    ---

"These presentations by our academic collaborators demonstrate our commitment to the transplant community, and the potential for clazakizumab to become a beneficial treatment for kidney transplant recipients with chronic active antibody mediated rejection of their allograft," said Dr. Eddie Chong, Chief Medical Officer, Vitaeris.

Abstracts can be accessed at the conference website: https://atcmeetingabstracts.com/search

Clazakizumab has been specially engineered to remove antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Clazakizumab has been administered in clinical trials involving over one thousand patients and has performed well against safety and efficacy criteria with acceptable tolerability in autoimmune diseases.

About Vitaeris

Vitaeris Inc. is a privately held, clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic inflammatory diseases. IL-6 is a key cytokine involved in the inflammation of rheumatoid arthritis and is now being implicated in numerous other diseases characterized by chronic inflammation, including solid organ graft rejection. Clazakizumab has been studied in clinical trials involving over one thousand patients worldwide, and was licensed on an exclusive, worldwide basis from Alder Biopharmaceuticals. Vitaeris' shareholders include key founding investor HBM Healthcare Investments, key founder Alder, Vitaeris' co-founders and other private investors. In December 2017, Vitaeris and CSL Limited announced a strategic partnership with option to acquire.

For more information about Vitaeris, visit www.vitaerisbio.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/vitaeris-announces-multiple-scientific-presentations-involving-clazakizumab-at-the-2019-american-transplant-congress-300854653.html

SOURCE Vitaeris